Axa S.A. Intellia Therapeutics, Inc. Transaction History

Axa S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $195,871 - $269,714	8,223 New	8,223 $226,000
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $1.27 Million - $2.4 Million	-38,287 Closed	0 $0
Q3 2022 Feb 14, 2023	BUY	$53.92 - $71.7 $8,842 - $11,758	164 Added 0.43%	38,287 $2.14 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $8,842 - $11,758	164 Added 0.43%	38,287 $2.14 Million
Q2 2022 Feb 14, 2023	SELL	$38.49 - $76.21 $28,521 - $56,471	-741 Reduced 1.91%	38,123 $1.97 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $28,521 - $56,471	-741 Reduced 1.91%	38,123 $1.97 Million
Q1 2022 Feb 14, 2023	BUY	$58.27 - $118.99 $33,621 - $68,657	577 Added 1.51%	38,864 $2.82 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $46,651 - $64,060	463 Added 1.21%	38,864 $4.6 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $187,303 - $250,143	1,415 Added 3.83%	38,401 $5.15 Million
Q2 2021 Aug 13, 2021	BUY	$60.88 - $161.91 $2.25 Million - $5.99 Million	36,986 New	36,986 $5.99 Million

316

91.7M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $722M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.